Long-term health outcomes for lecanemab using simulation model and Phase 3 Clarity AD data published
Stockholm, April 4, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that its partner Eisai has published an article about long-term health outcomes of anti-amyloid-beta (Aβ) protofibril[1] antibody lecanemab in people living with mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) using a disease simulation model in the peer-reviewed journal Neurology and Therapy . In this simulation, lecanemab treatment is estimated to potentially slow the rate of